SCHEMBL12895145

SCHEMBL12895145

c1cnc2c(c1)CCC(NC1=NCCS1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 4/20 0.39
GRIN2B Q13224 4/20 0.39
POLB P06746 1/20 0.36
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
HDAC8 Q9BY41 2/20 0.33
HDAC6 Q9UBN7 2/20 0.33
MAPK1 P28482 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
SCN1A P35498 1/20 0.32
SCN5A Q14524 1/20 0.32
SCN8A Q9UQD0 1/20 0.32
HSD17B10 Q99714 1/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750599 0.76 ATM (0.43) POLBMAPK1SMN1; SMN2ALDH1A1HSD17B10
SCHEMBL9449692 0.75 GRIN2B (0.50) GRIN1GRIN2BDRD2DRD3HDAC8
SCHEMBL4667034 0.74 POLB (0.50) POLBMAPK1SMN1; SMN2ALDH1A1GAA
SCHEMBL7472586 0.73 DRD2 (0.48) GRIN1GRIN2BDRD2DRD3MAPK1
SCHEMBL8783223 0.70 GRIN2B (0.50) GRIN1GRIN2BDRD2DRD3HDAC8
SCHEMBL3756960 0.69 CA1 (0.54) DRD2DRD3SMN1; SMN2GAANPC1
SCHEMBL1993959 0.69 LMNA (0.49) POLBLMNA
SCHEMBL8783295 0.68 GRIN1 (0.54) GRIN1GRIN2BDRD2DRD3
SCHEMBL3311831 0.68 MTNR1A (0.64) GRIN1GRIN2BMAPK1
SCHEMBL8783707 0.67 GRIN2B (0.67) GRIN1GRIN2BDRD2DRD3HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486969-B2 Therapeutic compounds ALLERGAN, INC. (US) 2013-07-16 US disclosed
US-20110039864-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2011-02-17 US disclosed
WO-2009023752-A1 ADRENERGIC COMPOUNDS ALLERGAN, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039864-A1 THERAPEUTIC COMPOUNDS ADRB2, ADRB1, ADRB3 GRIN1 878/4885GRIN2B 1108/4885POLB 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.